LB Pharmaceuticals Inc reported a net loss of $51.6 million for the quarter ended June 30, 2026, driven by a surge in research and development expenses to $44.1 million as it advances its lead asset, LB-102. The company announced that enrollment in the pivotal Phase 3 NOVA-2 trial for schizophrenia is ahead of schedule, projecting topline data readout in the first half of 2027, with a pre-NDA meeting planned for the second half of 2027. Additionally, LB Pharmaceuticals completed a $150 million private placement in July 2026 to fund pipeline expansion into new neuropsychiatric indications and general corporate purposes. As of June 30, 2026, the company held $327.8 million in cash, cash equivalents, and marketable securities, which is expected to support operations beyond the second quarter of 2029. The company also appointed Christopher Zergebel as Senior Vice President, Clinical Operations. LB Pharmaceuticals operates in the biotechnology industry, focusing on developing neuromedicines for underserved brain diseases.
